34 completed, 28 recruiting, 28 unknown, 16 not yet recruiting. 52 Phase 1, 24 Phase 3, 23 Phase 2, 11 Phase 4, 3 Not applicable.
Follow Changchun GeneScience Pharmaceutical Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I Study of GenSci148 Intravitreal Injection for Neovascular Age-related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion GenSci148 Injection - Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME) | Phase 1 | Not yet recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 60 | 2026-09-01 | 2026-09-14 |
| A Phase III Clinical Study of Jinpei Growth Hormone Injection in the Treatment of Short Stature Children With Small for Gestational Age (SGA) PEG-hGH Injection, hGH Injection - Small for Gestational Age | Phase 3 | Not yet recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 105 | 2026-09-01 | 2026-09-25 |
| Phase 1 Clinical Study of GenSci164 Injection GenSci164 Injection, Placebo - Healthy Adult Trial Participants | Phase 1 | Not yet recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 56 | 2026-08-24 | 2026-08-27 |
| A Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Intravaginal Doses of GenSci142 in Patients With Bacterial Vaginosis (BV) GenSci142 capsule, clindamycin phosphate vaginal cream - Randomized, Open-label | Phase 1 | Recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 42 | 2026-08-15 | 2026-10-15 |
| Phase 1 Clinical Study of GenSci155 Injection in Healthy Adults GenSci155 Injection, Placebo - Healthy Adult Trial Participants | Phase 1 | Not yet recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 68 | 2026-07-28 | 2026-06-10 |
| A Study of Efficacy and Safety of GenSci048 in Subjects With Active Uveitis. GenSci048, Placebo - Uveitis | Phase 2 | Recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 74 | 2026-06-29 | 2026-07-24 |
| GenSci144 Tablets Phase I Clinical Trial GenSci144 tablets, GenSci144 placebo tablets - Phenylketonuria | Phase 1 | Recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 48 | 2026-06-22 | 2026-07-06 |
| To Evaluate the Impact of Smoking on PK After Single-dose Oral Administration of GS1-144 Tablets . GS1-144 tablets - Postmenopause | Phase 1 | Completed | Changchun GeneScience Pharmaceutical Co., Ltd. | 24 | 2026-05-20 | 2026-09-18 |
| Safety and Efficacy of Corifollitropin Alfa N02 Injection in Elderly Women Undergoing Assisted Reproductive Technology (ART) NA，Observational study - Infertility | Not yet recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 200 | 2026-05-01 | 2026-04-28 | |
| Phase IIb Clinical Study to Assess the Efficacy and Safety of GenSci120 Injection in Patients With Moderately to Severely Active RA Who Have an Inadequate Response to at Least One DMARD GenSci120 150 mg, GenSci120 600 mg, GenSci120 1000 mg - Rheumatoid Arthritis | Phase 2 | Recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 450 | 2026-04-30 | 2026-05-22 |
| GS1-144 in Participants With Hepatic Impairment and Healthy Female GS1-144 tablet - Hepatic Impairment and Healthy Female | Phase 1 | Not yet recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 24 | 2026-04-20 | 2026-03-24 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics of GenSci161 in Healthy Adult Participants GenSci161, Placebo - Healthy Volunteers | Phase 1 | Recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 44 | 2026-04-20 | 2026-05-01 |
| A Clinical Study to Evaluate the Absorption, Metabolism, and Excretion of Oral [14C]GS1-144 in Healthy Postmenopausal Female Participants [14C]GS1-144 - Healthy Postmenopausal Women, Absorption | Phase 1 | Active not recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 6 | 2026-04-09 | 2026-05-07 |
| GenSci145 as Monotherapy or in Combination Therapy, in Participants With PIK3CA-mutated, Locally Advanced or Metastatic Solid Tumors. GenSci145 tablets - Locally Advanced or Metastatic Solid Tumors With PIK3CA-mutated | Phase 1 | Recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 186 | 2026-04-01 | 2026-09-25 |
| A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci136 in Healthy Adults. GenSci136, Placebo - Autoimmune Disease | Phase 1 | Recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 56 | 2026-03-16 | 2026-10-14 |
| A Study of GenSci134 in Children With Growth Hormone Deficiency (PGHD) GenSci134 Injection, Recombinant Human Growth Hormone Injection(Norditropin® FlexPro®) - Pediatric Growth Hormone Deficiency | Phase 1 / Phase 2 | Not yet recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 128 | 2026-03-06 | 2026-03-04 |
| A Study (Phase 1b/2) of GenSci134 in Children With Idiopathic Short Stature (ISS) GenSci134 Injection, Recombinant Human Growth Hormone Injection(Norditropin® FlexPro®) - Idiopathic Short Stature | Phase 1 / Phase 2 | Not yet recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 128 | 2026-03-06 | 2026-03-04 |
| A Study (Phase 1b/2) of GS3-007a Oral Treatment in Children With Growth Hormone Deficiency (PGHD) GS3-007a dry suspension, Placebo for GS3-007a dry suspension, rhGH injection - Pediatric Growth Hormone Deficiency | Phase 1 / Phase 2 | Recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 88 | 2026-01-18 | 2026-09-16 |
| Nanocrystalline Megestrol Acetate for Cachectic Stage Locally Advanced Hepatocellular Carcinoma Nanocrystalline Megestrol Acetate, Standard Antitumor Therapy - Cachexia, Hepatocellular Carcinoma | Phase 3 | Not yet recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 68 | 2026-01-10 | 2026-01-21 |
| A Study（Phase I）of GS3-007a Dry Suspension in Healthy Chinese Adults GS3-007a for Suspension, Placebo GS3-007a for Suspension - Healthy Adults | Phase 1 | Recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 32 | 2026-01-07 | 2026-03-16 |
Showing 20 of 116. Sign in to see all of them.
Dwarfism, Pituitary (13) · Dwarfism (4) · Infertility (4) · Arthritis, Rheumatoid (2) · Autoimmune Diseases (2) · Cachexia (2) · Carcinoma, Hepatocellular (2) · Carcinoma, Non-Small-Cell Lung (2) · Hyperprolactinemia (2) · Turner Syndrome (2) · Vaginosis, Bacterial (2) · Achondroplasia (1) · Anovulation (1) · Arthritis, Gouty (1) · Arthritis, Juvenile (1)
polyethylene glycol-recombinant human growth hormone (9) · Injections (8) · Growth Hormone (7) · Human Growth Hormone (7) · Standard of Care (3) · Cabergoline (2) · Colchicine (2) · Population Groups (2) · follitropin alfa (2) · Adalimumab (1) · Bromocriptine (1) · Genetic Testing (1) · Insulin (1) · Leuprolide (1) · Paclitaxel (1)
China (108) · United States (2) · Australia (1) · Puerto Rico (1) · Taiwan (1)
Xiaoping Luo (4) · Hejian Zou (3) · Feihong Luo, Doctor (2) · Jian Zhang, Doctor (2) · Jin Li (2) · Xiaolan Yong, bachelor (2) · Bassem Elmankabadi (1) · Bradley Miller (1) · Cheng Du (1) · Chunxiu Gong (1) · Chunxiu Gong, PhD (1) · Chunxiu Gong, doctor (1) · Feihong Luo (1) · Guimei Li (1)
PMID 28566441, PMID 39513569, PMID 34899612, PMID 35573994, PMID 35945517, PMID 36034802, PMID 36669772, PMID 40711661, PMID 40833487, PMID 41814037, PMID 42154367, PMID 42498684, PMID 42871009
2025 (1)